What is the official website of MSD Manufacturing Division (MMD) Haarlem ?

The official website of MSD Manufacturing Division (MMD) Haarlem is http://www.werkenbijmsd.nl.

What is MSD Manufacturing Division (MMD) Haarlem's cybersecurity risk score?

MSD Manufacturing Division (MMD) Haarlem has an AI-generated cybersecurity risk score of 770 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has MSD Manufacturing Division (MMD) Haarlem experienced?

According to Rankiteo, MSD Manufacturing Division (MMD) Haarlem currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has MSD Manufacturing Division (MMD) Haarlem been affected by any supply chain cyber incidents ?

According to Rankiteo, MSD Manufacturing Division (MMD) Haarlem has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does MSD Manufacturing Division (MMD) Haarlem have SOC 2 Type 1 certification ?

According to Rankiteo, MSD Manufacturing Division (MMD) Haarlem is not certified under SOC 2 Type 1.

Does MSD Manufacturing Division (MMD) Haarlem have SOC 2 Type 2 certification ?

According to Rankiteo, MSD Manufacturing Division (MMD) Haarlem does not hold a SOC 2 Type 2 certification.

Does MSD Manufacturing Division (MMD) Haarlem comply with GDPR ?

According to Rankiteo, MSD Manufacturing Division (MMD) Haarlem is not listed as GDPR compliant.

Does MSD Manufacturing Division (MMD) Haarlem have PCI DSS certification ?

According to Rankiteo, MSD Manufacturing Division (MMD) Haarlem does not currently maintain PCI DSS compliance.

Does MSD Manufacturing Division (MMD) Haarlem comply with HIPAA ?

According to Rankiteo, MSD Manufacturing Division (MMD) Haarlem is not compliant with HIPAA regulations.

Does MSD Manufacturing Division (MMD) Haarlem have ISO 27001 certification ?

According to Rankiteo,MSD Manufacturing Division (MMD) Haarlem is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does MSD Manufacturing Division (MMD) Haarlem operate in ?

MSD Manufacturing Division (MMD) Haarlem operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does MSD Manufacturing Division (MMD) Haarlem have ?

MSD Manufacturing Division (MMD) Haarlem employs approximately None employees people worldwide.

Does MSD Manufacturing Division (MMD) Haarlem own any subsidiaries ?

MSD Manufacturing Division (MMD) Haarlem presently has no subsidiaries across any sectors.

How many LinkedIn followers does MSD Manufacturing Division (MMD) Haarlem have ?

MSD Manufacturing Division (MMD) Haarlem's official LinkedIn profile has approximately followers.

What is the NAICS classification code for MSD Manufacturing Division (MMD) Haarlem ?

MSD Manufacturing Division (MMD) Haarlem is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does MSD Manufacturing Division (MMD) Haarlem have a Crunchbase profile ?

No, MSD Manufacturing Division (MMD) Haarlem does not have a profile on Crunchbase.

Does MSD Manufacturing Division (MMD) Haarlem have a LinkedIn profile ?

Yes, MSD Manufacturing Division (MMD) Haarlem maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/msd-manufacturing-division-mmd-haarlem.

How many cybersecurity incidents has MSD Manufacturing Division (MMD) Haarlem experienced ?

As of September 26, 2026, Rankiteo reports that MSD Manufacturing Division (MMD) Haarlem has experienced 1 cybersecurity incidents.

How many peer or competitor companies does MSD Manufacturing Division (MMD) Haarlem have ?

MSD Manufacturing Division (MMD) Haarlem has an estimated 5,769 peer or competitor companies worldwide.

What types of cybersecurity incidents has MSD Manufacturing Division (MMD) Haarlem faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Breach.

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

MMDH

Boost Score +25 with badge (5 left)

770

/1000

Fair

795

/1000

Fair

MSD Manufacturing Division (MMD) Haarlem Vendor Cyber Rating & Cyber Score

werkenbijmsd.nl

Add Your Compliance Badge

MMD Haarlem produceert, verpakt en distribueert op hoge kwaliteit medicijnen. De tabletten in potjes en blisters, tot aan poeders worden via Haarlem naar meer dan 140 landen getransporteerd.

MMDH

MSD Manufacturing Division (MMD) Haarlem CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

MSD Manufacturing D...

Breach

9/2025

MSD060270611182...

Loading…

A.I.

MMDH Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for MMDH

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for MSD Manufacturing Division (MMD) Haarlem in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for MSD Manufacturing Division (MMD) Haarlem in 2026.

Incident Types MMDH vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for MSD Manufacturing Division (MMD) Haarlem in 2026.

Incident History - MMDH (X = Date, Y = Severity)

Loading…

SUBSIDIARY

MSD Manufacturing Division (MMD) Haarlem Subsidiaries

MMDH

Pharmaceutical Manufacturing

Website: http://www.werkenbijmsd.nl

Company Size: None employees

MSDPharmaceutical Manufacturing

MSD Animal HealthPharmaceutical Manufacturing

MSD LATAMPharmaceutical Manufacturing

MSD Saúde AnimalVeterinary Services

MSD EspañaPharmaceutical Manufacturing

MSD EgyptPharmaceutical Manufacturing

MSD DeutschlandPharmaceutical Manufacturing

MSD FrancePharmaceutical Manufacturing

MSD GCCPharmaceutical Manufacturing

MSD SwitzerlandPharmaceutical Manufacturing

MSD PortugalPharmaceutical Manufacturing

MSD TürkiyePharmaceutical Manufacturing

MSD ItaliaPharmaceutical Manufacturing

MSDsalutePharmaceutical Manufacturing

MSD ÖsterreichPharmaceutical Manufacturing

MSD RomaniaPharmaceutical Manufacturing

MSD Australia & New ZealandPharmaceutical Manufacturing

MSD DanmarkPharmaceutical Manufacturing

MSD SlovenskoPharmaceutical Manufacturing

MSD UkrainePharmaceutical Manufacturing

MSD JordanPharmaceutical Manufacturing

MSD Animal Health UK LtdPharmaceutical Manufacturing

MSD SverigePharmaceutical Manufacturing

MSD GreecePharmaceutical Manufacturing

MSD Animal Health Technology LabsTechnology, Information and Internet

MSD NorgePharmaceutical Manufacturing

MSD in the UKPharmaceutical Manufacturing

MSD BelgiumPharmaceutical Manufacturing

MSD Czech RepublicPharmaceutical Manufacturing

MSD LebanonPharmaceutical Manufacturing

MSD MagyarországPharmaceutical Manufacturing

MSD SRBIJAPharmaceutical Manufacturing

MSD PolskaPharmaceutical Manufacturing

MSD FinlandPharmaceutical Manufacturing

MSD South AfricaPharmaceutical Manufacturing

MSD NetherlandsPharmaceutical Manufacturing

Curare MagazineHospitals and Health Care

MSD & diabetesHospitals and Health Care

MSD AcademyHospitals and Health Care

Loading…

MSD Manufacturing Division (MMD) Haarlem Similar Companies

MACLEODS PHARMACEUTICALS LTD.

macleodspharma.com

A vertically integrated, Global Pharmaceutical Company. Established in 1989, we are engaged in developing, manufacturing, and marketing a wide range of formulations across several major therapeutic areas including anti-infectives, cardiovascular, anti-diabetic, dermatology, and hormone treatment. We develop, manufacture, and globally distribute a broad range of pharmaceutical products across therapies in multiple dosage forms such as solid orals, liquid orals, topical formulations, injectables (Dry Powder) metered dose inhalers and dry powder inhalers. Our Vision To be a leading global pharmaceutical company by providing high quality, affordable and innovative therapeutic solutions for patients with diverse medical needs. Our Mission To contribute towards improving patients’ quality of life across the globe, by providing effective and accessible medicines.

Grifols

cb linktr.ee

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world. A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions in more than 110 countries. Patient needs and our ever-growing knowledge of many chronic, rare and prevalent diseases, sometimes life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases. With a workforce of over 23,000 employees in more than 30 countries and regions, we are committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry. Our work has a positive social and economic impact in the countries where we operate, creating jobs and generating wealth. People are at the heart of what we do, and we strive to create an inclusive, diverse, fair and equal society. Maintaining and promoting a workforce that reflects this reality leads to enhanced professional relationships and helps us to give our best to patients, donors and customers. In 2024, Grifols was named one of TIME’s ‘World’s Best Companies’ for the second year in a row, reaffirming our commitment to excellence. We were also recognized by Forbes as one of the "Best Employers for Women 2023," reflecting our dedication to fostering an inclusive and supportive workplace for all. To maintain a positive community and overall respectful communication, please keep our community guidelines in mind.

Glenmark Pharmaceuticals

glenmarkpharma.com

Glenmark Pharmaceuticals Limited is a research-led, global organization committed to enriching lives. Innovation is deeply embedded in Glenmark’s culture; it is how we differentiate ourselves in our key markets and create greater value for our stakeholders. In our journey of innovation over the past four and a half decades, we have evolved from a generics company to a global organization offering specialty and branded products. Glenmark’s core values of Achievement, Respect, and Knowledge impart a sense of organizational unity that drives our growth. We have established a robust global branded generics, specialty, and OTC business; with a significant presence in the therapy areas of dermatology, respiratory, and oncology. Our ten state-of-the-art manufacturing facilities spread across four continents with operations in over 80 countries help us impact millions of patients across the globe. We recently consolidated our innovation efforts in small molecules and biologics research with the formation of ‘Ichnos Glenmark Innovation’ (IGI). This alliance is aimed at leveraging the capabilities of Glenmark and its subsidiary, Ichnos Sciences, to accelerate innovation in cancer treatment. To know more about IGI, check out: https://iginnovate.com/ Sustainability is an integral aspect of all our operations and we are focused on achieving our Environment, Social and Governance (ESG) goals. Our responsibility also extends to our communities, and over the years, our CSR efforts have touched the lives of over 3 million people.

Viatris

viatris.com

Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale. In 2022 alone, we supplied high-quality medicines to approximately 1 billion patients around the world. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world’s most enduring health challenges, access takes on deep meaning at Viatris. We have the ability to touch all of life’s moments, from birth to end of life, acute conditions to chronic diseases. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India Social Media Guidelines: https://newsroom.viatris.com/social-media-community-guidelines Investors: https://investor.viatris.com Corporate Social Responsibility: https://www.viatris.com/sustainability Connect with Viatris Instagram: https://www.instagram.com/viatrisinc X: https://www.x.com/viatrisinc Viatris and our recruiting firms will not ask for sensitive personal information, such as your social security number, date of birth or bank account details via text, email or social media. Additionally, Viatris representatives do not request payment or personal bank information nor send payment to purchase hardware on your own. Viatris.com is the primary source of all company job postings and authorized third-party career websites.

Novo Nordisk

cb novonordisk.com

We’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic disease and create long-term health. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and work to treat, prevent, and even cure diseases that affect millions of lives. Founded in Denmark in 1923, today we employ more than 68,800 people in 80 offices around the world – all united by our bold purpose to drive change to defeat serious chronic diseases. Want to learn more? Visit www.novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to block and remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html

Servier

servier.com

Servier is an independent international pharmaceutical group governed by a foundation. With its unique governance model, the Group is committed to therapeutic progress to serve patients and integrates the patient voice at every stage of the medicine life cycle. As a leading global player in cardiology and venous diseases, Servier aims to become a leading innovator in oncology and neurology. Through precision medicine, the Group intends to offer targeted therapeutic solutions for a limited number of rare diseases and invests nearly 20% of its brand-name sales in R&D. Headquartered in France, Servier relies on its more than 20,000 employees and a solid geographic presence with medicines distributed in more than 130 countries. In the 2024/25 financial year, the Group achieved revenues of €6.9 billion. -- To report a suspected adverse event with a Servier drug, please visit servier.com

Astellas Pharma

astellas.com

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Visit our Global Astellas LinkedIn Community Guidelines to learn more about interacting with this page: https://www.astellas.com/en/global-linkedin-community-guidelines

Teva Pharmaceuticals

tevapharm.com

Teva Pharmaceuticals is a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how we make it happen, visit www.tevapharm.com. Our community guidelines may be found here: https://www.tevapharm.com/news-and-media/teva-social-media-guidelines/ Please note that adverse effects for any of our products should be reported at: https://www.tevapharm.com/teva-medical-information/report-a-side-effect-form/ Product-specific questions should be directed to Teva or Teva Group subsidiaries in your country. Contact details and Teva's Pharmacovigilance Privacy Policy may be found here: http://www.tevapharm.com/contact_us/

Torrent Pharmaceuticals Ltd

cb torrentpharma.com

Torrent Pharma, with annual revenues of more than Rs 10,700 crores, is the flagship Company of the Torrent Group, with group revenues of Rs 41,000 crores. It is ranked 5th in the Indian Pharma Market and is among the Top 5 in the therapeutic segments of Cardiovascular (CV), Central Nervous System (CNS), Gastro-intestinal (GI), Vitamins Minerals Nutritionals (VMN) and Cosmo-Dermatology. The Company also has significant presence in diabetology, pain management, gynaecology, oncology and anti-infective segments. Torrent has 8 manufacturing facilities , of which 5 are USFDA approved. With R&D as the backbone for its growth in domestic & overseas market, it has invested significantly in R&D capabilities with state-of-the-art R&D infrastructure employing around 800 scientists. The acquisition of Elder Pharma's Indian branded business in 2013, Dermaceuticals business of Zyg Pharma in 2015, API plant of Glochem Industries in 2016, Women healthcare brands from Novartis and Unichem's Indian branded business along with its Sikkim Plant in 2017 strengthened Torrent Pharma's position in the Indian Pharma market. Torrent Pharma started international acquisitions in 2005 with entry into the German market. Today, the Company has presence in more than 50 countries and is ranked No. 1 among the Indian pharma Companies in Brazil and Germany. Torrent Pharma is committed towards “not just healthcare but lifecare.”

Loading…

NEWS

MSD Manufacturing Division (MMD) Haarlem CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-96795

SUMMARY

Horilla is an HR and CRM software. Prior to 2.0.0, HorillaListView.export_data in horilla_views/generic/cbv/views.py accepts an authenticated user's columns POST parameter, takes field_tuple[1], interpolates it into dynamic_fn_str as Python source, and passes the generated function definition to exec(). A crafted string that remains valid under ast.literal_eval can inject Python syntax into a default argument evaluated during function definition, allowing arbitrary operating-system commands to execute with the application process privileges, including root privileges in the shipped Docker image. This issue is fixed in version 2.0.0.

Published

Date2026-09-25

Updated

Date2026-09-25

RISK INFORMATION (Score: 8.8)

cvss3

Base Score: 8.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H

Impact Score

5.9

Exploitability

2.8

REFERENCES

CVE-2026-86066

SUMMARY

Horilla is an HR and CRM software. Prior to 2.0.0, approve_validate_attendance_request at /attendance/approve-validate-attendance-request/ changes attendance_validated, is_validate_request_approved, approved_by, and related pending-request state through an HTTP GET before calling attendance.save(), so Django does not require CSRF validation for the action. An unauthenticated attacker can cause a logged-in manager with attendance.change_attendance to make a top-level request that carries the manager's SameSite=Lax session cookie, silently approving attendance with the victim's privileges and attributing the approval to the victim in the audit trail. This issue is fixed in version 2.0.0.

Published

Date2026-09-25

Updated

Date2026-09-25

RISK INFORMATION (Score: )

cvss4

Base Score: 5.9

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:A/VC:N/VI:H/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

CVE-2026-57449

SUMMARY

Actual is a local-first personal finance tool. Prior to 26.7.0, Actual Sync Server's CORS proxy is intended to let authenticated users fetch resources only from repositories listed in the official plugin allowlist. When `ACTUAL_GITHUB_TOKEN` is configured, the proxy automatically attaches the server's GitHub token to GitHub requests. The GitHub API allowlist check uses a raw `startsWith()` prefix test for `/repos/{owner}/{repo}` without requiring a path boundary after the repository name. If an allowlisted public plugin repository is `https://github.com/acme/plugin`, the proxy also accepts GitHub API URLs. Those URLs are outside the allowlisted repository but still pass because their API path starts with `/repos/acme/plugin`. The proxy then forwards the request with the server's `ACTUAL_GITHUB_TOKEN`, allowing any authenticated Actual user to read private GitHub resources reachable by that token. Version 26.7.0 fixes the issue.

Published

Date2026-09-25

Updated

Date2026-09-25

RISK INFORMATION (Score: )

cvss4

Base Score: 7.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:H/VI:N/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

https://github.com/actualbudget/actual/security/advisories/GHSA-m62c-5q34-f3cf

CVE-2026-92842

SUMMARY

The convert.base64-encode, convert.quoted-printable-encode and convert.quoted-printable-decode stream filters accept a line-break-chars option whose length is tracked separately from the string itself. The filter constructors duplicate the value with pestrdup(), which stops at the first NUL byte, while keeping the original length. When the filter later emits a line break it copies the recorded length out of the truncated allocation, reading past its end and placing adjacent heap bytes into the filter output.

Published

Date2026-09-25

Updated

Date2026-09-25

RISK INFORMATION (Score: 5.9)

cvss3

Base Score: 5.9

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:H/I:N/A:N

Impact Score

3.6

Exploitability

2.2

REFERENCES

https://github.com/php/php-src/security/advisories/GHSA-88hq-2827-7pg6

CVE-2026-91768

SUMMARY

The IPv6 branch of the FastCGI client access check compares only the first 12 bytes of a 16-byte IPv6 address, so listen.allowed_clients matches on a /96 prefix instead of the exact address. An attacker who can source an address sharing the first 96 bits with an allowed one passes the check and reaches the FastCGI endpoint.

Published

Date2026-09-25

Updated

Date2026-09-25

RISK INFORMATION (Score: 6.5)

cvss3

Base Score: 6.5

Complexity: LOW

CVSS:3.1/AV:A/AC:L/PR:N/UI:N/S:U/C:H/I:N/A:N

Impact Score

3.6

Exploitability

2.8

REFERENCES

https://github.com/php/php-src/security/advisories/GHSA-62xp-839h-2637

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…

Badge your company to reduce your risk score and your cyber insurance costs!

Trusted by insurers. Chosen by leaders.

MSD Manufacturing Division (MMD) Haarlem Vendor Cyber Rating & Cyber Score

MMDH A.I CyberSecurity Scoring

MSD Manufacturing Division (MMD) Haarlem CyberSecurity News & History

MMDH Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for MMDH

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types MMDH vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - MMDH (X = Date, Y = Severity)

MSD Manufacturing Division (MMD) Haarlem Subsidiaries

MMDH

MSD Manufacturing Division (MMD) Haarlem Similar Companies

MACLEODS PHARMACEUTICALS LTD.

Grifols

Glenmark Pharmaceuticals

Viatris

Novo Nordisk

Servier

Astellas Pharma

Teva Pharmaceuticals

Torrent Pharmaceuticals Ltd

MSD Manufacturing Division (MMD) Haarlem CyberSecurity News

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo

MSD Manufacturing Division (MMD) Haarlem CyberSecurity News & History

MMDH Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for MMDH

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types MMDH vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - MMDH (X = Date, Y = Severity)

MSD Manufacturing Division (MMD) Haarlem Subsidiaries

MMDH

MSD Manufacturing Division (MMD) Haarlem Similar Companies

MACLEODS PHARMACEUTICALS LTD.

Grifols

Glenmark Pharmaceuticals

Viatris

Novo Nordisk

Servier

Astellas Pharma

Teva Pharmaceuticals

Torrent Pharmaceuticals Ltd

MSD Manufacturing Division (MMD) Haarlem CyberSecurity News

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo